Cargando…

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial

Detalles Bibliográficos
Autores principales:	Marmorino, Federica, Falcone, Alfredo, Cremolini, Chiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497461/ https://www.ncbi.nlm.nih.gov/pubmed/31073370 http://dx.doi.org/10.18632/oncotarget.26870

Ejemplares similares

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

mCRC: rasante Weiterentwicklung zielgerichteter Therapien
por: Arnheim, Katharina
Publicado: (2022)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
por: Feliu, J, et al.
Publicado: (2014)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
por: Rossi, Luigi, et al.
Publicado: (2013)

First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview
por: Martín-Richard, Marta, et al.
Publicado: (2021)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients
por: Yu, Ping, et al.
Publicado: (2018)

Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment
por: Chen, Hong-Hwa, et al.
Publicado: (2021)

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
por: Saif, Muhammad Wasif
Publicado: (2013)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial
por: Ferreira, Cláudia S., et al.
Publicado: (2023)

Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC)
por: Tysarowski, Andrzej, et al.
Publicado: (2018)

Maximising clinical benefit with adequate patient management beyond the second line in mCRC
por: Argiles, Guillem, et al.
Publicado: (2019)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
por: Marmorino, Federica, et al.
Publicado: (2020)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
por: Bahl, Ankur, et al.
Publicado: (2020)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
por: Zhang, Yiyi, et al.
Publicado: (2021)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
por: Prager, Gerald, et al.
Publicado: (2021)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
por: Schulz, Martin S., et al.
Publicado: (2022)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
por: Borelli, Beatrice, et al.
Publicado: (2022)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy
por: Faruk Aykan, N., et al.
Publicado: (2013)

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
por: Souglakos, J, et al.
Publicado: (2012)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

Tumor Response to Irinotecan is Associated with IL-10 Expression Level in Metastatic Colorectal Cancer-Results from mCRC Biomarker Study
por: Chang, Jinjia, et al.
Publicado: (2020)

Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy
por: Quirino, Michela, et al.
Publicado: (2017)

Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development
por: Gmeiner, William H
Publicado: (2021)

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression–free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy
por: Pohl, Alexandra, et al.
Publicado: (2012)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
por: Kurreck, A., et al.
Publicado: (2020)

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial
por: Stintzing, Sebastian, et al.
Publicado: (2018)

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
por: Patel, Gargi S, et al.
Publicado: (2015)

Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis
por: Zheng, Peng, et al.
Publicado: (2018)

A National Survey of Medical Oncologist’s Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab
por: Lowe, Kimberly A., et al.
Publicado: (2019)

Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomes—The University College London Hospital (UCLH) Experience
por: Joharatnam-Hogan, Nalinie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c2vq0uro64m6f6ti2klqvv0pgc